Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial

被引：0
|
作者：
John K. Botson
Katie Obermeyer
Brian LaMoreaux
Lin Zhao
Michael E. Weinblatt
Jeff Peterson
机构：
[1] Orthopedic Physicians Alaska,Division of Rheumatology, Immunology and Immunity
[2] Horizon Therapeutics plc,undefined
[3] Brigham and Women’s Hospital,undefined
[4] Western Washington Arthritis Clinic,undefined
来源：
Arthritis Research & Therapy | / 24卷
关键词：
Pegloticase; Uncontrolled gout; Refractory gout; Immunomodulation; Methotrexate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 15 条
  • [1] Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial
    Botson, John K. K.
    Obermeyer, Katie
    LaMoreaux, Brian
    Zhao, Lin
    Weinblatt, Michael E. E.
    Peterson, Jeff
    ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
  • [2] PEGLOTICASE/METHOTREXATE CO-THERAPY IMPROVED JOINT AND PATIENT-REPORTED HEALTH ASSESSMENTS IN PATIENTS WITH UNCONTROLLED GOUT: 12-MONTH EXPLORATORY OUTCOMES OF THE MIRROR OPEN-LABEL TRIAL
    Botson, J.
    Peloso, P. M.
    Obermeyer, K.
    Lamoreaux, B.
    Zhao, L.
    Weinblatt, M. E.
    Peterson, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1348 - 1349
  • [3] A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study
    Botson, John
    Peloso, Paul
    Obermeyer, Katie
    LaMoreaux, Brian
    Zhao, Lin
    Weinblatt, Michael
    Peterson, Jeff
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [4] PEGLOTICASE plus METHOTREXATE COTHERAPY IN UNCONTROLLED GOUT PATIENTS WITH PRIOR PEGLOTICASE MONOTHERAPY FAILURE: FINDINGS OF THE ADVANCE OPEN-LABEL TRIAL
    Troum, O.
    Botson, J.
    Obermeyer, K.
    Verma, S.
    Lamoreaux, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1853 - 1854
  • [5] PEGLOTICASE RESPONSE IMPROVEMENT BY CO-TREATMENT WITH METHOTREXATE: RESULTS FROM THE MIRROR OPEN-LABEL CLINICAL TRIAL IN PATIENTS WITH UNCONTROLLED GOUT
    Botson, J.
    Peloso, P. M.
    Obermeyer, K.
    Lamoreaux, B.
    Weinblatt, M. E.
    Peterson, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 442 - 442
  • [6] Quality of life and clinical gout assessments during pegloticase with and without methotrexate co-therapy: MIRROR randomized controlled trial exploratory findings
    Botson, John
    Obermeyer, Katie
    Lamoreaux, Brian
    Padnick-Silver, Lissa
    Verma, Supra
    Weinblatt, Michael E.
    Peterson, Jeff
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2024, 8 (04)
  • [7] A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study
    John K. Botson
    John R. P. Tesser
    Ralph Bennett
    Howard M. Kenney
    Paul M. Peloso
    Katie Obermeyer
    Yang Song
    Brian LaMoreaux
    Lin Zhao
    Yan Xin
    Jason Chamberlain
    Srini Ramanathan
    Michael E. Weinblatt
    Jeff Peterson
    Arthritis Research & Therapy, 24
  • [8] A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study
    Botson, John K.
    Tesser, John R. P.
    Bennett, Ralph
    Kenney, Howard M.
    Peloso, Paul M.
    Obermeyer, Katie
    Song, Yang
    LaMoreaux, Brian
    Zhao, Lin
    Xin, Yan
    Chamberlain, Jason
    Ramanathan, Srini
    Weinblatt, Michael E.
    Peterson, Jeff
    ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
  • [9] Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
    Galle, Peter R.
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Zhu, Andrew X.
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Mulla, Sohail
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Ding, Beiying
    Liu, Juan
    Huang, Chen
    Lim, Ho Yeong
    Cheng, Ann-Lii
    Ducreux, Michel
    LANCET ONCOLOGY, 2021, 22 (07): : 991 - 1001
  • [10] Patient-reported outcomes with trastuzumab monotherapy versus trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT): A randomized, open-label, phase 3 clinical trial
    Kobayashi, K.
    Taira, N.
    Sawaki, M.
    Sagawa, N.
    Baba, S.
    Saito, T.
    Kawahara, T.
    Hagiwara, Y.
    Uemura, Y.
    Shimozuma, K.
    Ohashi, Y.
    Mukai, H.
    CANCER RESEARCH, 2019, 79 (04)
12